Unparalleled contribution of18F-FDG PET to medicine over 3 decades

Journal of Nuclear Medicine

Volumn 49, Issue 10, 2008, Pages

  Basu, Sandip ^a   Alavi, Abass ^b  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE 3 OCTREOTIDE GA 68; 2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE F 18; 3' DEOXY 3' FLUOROTHYMIDINE F 18; CARBON 11; COPPER 64; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE) CU 64; DIHYDROTETRABENAZINE C 11; FIALURIDINE I 124; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUORODOPA F 18; FLUOROESTRADIOL 17BETA F 18; FLUOROPROPIONYL TOCA F 18; GALACTO ARGININYLGLYCYLASPARTIC ACID F 18; GALLIUM 68; IODINE 124; METHYLPHENIDATE C 11; NITROGEN 13; OXYGEN 15; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; RUBIDIUM 82; SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ANGIOCARDIOGRAPHY; ATHEROSCLEROSIS; BACKACHE; BLOOD CLOT; CANCER STAGING; CARDIOLOGY; CHRONIC OSTEOMYELITIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIABETIC FOOT; GENE THERAPY; INFECTION; INFLAMMATION; ISOTOPE LABELING; LUNG DISEASE; MEDICAL TECHNOLOGY; MOLECULAR PROBE; NEUROLOGY; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; OSTEOARTHROPATHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUICIDE GENE THERAPY; VASCULITIS; BRAIN; DRUG DESIGN; HUMAN; METHODOLOGY; NUCLEAR MEDICINE; PATHOLOGY; REVIEW;

BRAIN; CARDIOLOGY; DRUG DESIGN; FLUORODEOXYGLUCOSE F18; HUMANS; MEDICAL ONCOLOGY; NEUROLOGY; NUCLEAR MEDICINE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 53749095638     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (78)

1. Alavi A, Reivich M. Guest editorial: the conception of FDG-PET imaging. Semin Nucl Med. 2002;32:2-5.
2. Lucignani G. Non-standard PET radionuclides: time to get ready for new clinical PET strategies. Eur J Nucl Med Mol Imaging. 2007;34:294-300.
3. Hicks RJ. Beyond FDG: novel PET tracers for cancer imaging. Cancer Imaging. 2003;4:22-24.
4. 18F-FDG and the novel quantitative approaches in PET imaging. Q J Nucl Med Mol Imaging. 2008;52:50-65.
5. Brady F, Luthra SK, Brown GD, et al. Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET. Curr Pharm Des. 2001;7:1863-1892.
6. Basu S, Zaidi H, Houseni M, et al. Novel quantitative techniques for assessing regional and global function and structure based on modern imaging modalities: implications for normal variation, aging and diseased states. Semin Nucl Med. 2007;37:223-239.
7. Weber WA, Schwaiger M, Avril N. Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol. 2000;27:683-687.
8. Basu S, Houseni M, Bural G, et al. Magnetic resonance imaging based bone marrow segmentation for quantitative calculation of pure red marrow metabolism using 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography: a novel application with significant implications for combined structure-function approach. Mol Imaging Biol. 2007;9:361-365.
9. Basu S, Alavi A. Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer? Eur J Nucl Med Mol Imaging. 2007;34:1527-1529.
10. Torigian DA, Huang SS, Houseni M, Alavi A. Functional imaging of cancer with emphasis on molecular techniques. CA Cancer J Clin. 2007;57:206-224.
11. Alavi A, Lakhani P, Mavi A, Kung JW, Zhuang H. PET: a revolution in medical imaging. Radiol Clin North Am. 2004;42:983-1001.
12. Basu S, Alavi A. Staging with PET and the "Will Rogers" effect: redefining prognosis and survival in patients with cancer. Eur J Nucl Med Mol Imaging. 2008;35:1-4.
13. Brepoels L, Stroobants S. Is [(18)F]fluorodeoxyglucose positron emission tomography the ultimate tool for response and prognosis assessment? Hematol Oncol Clin North Am. 2007;21:855-869.
14. Basu S, Chen W, Tchou J, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer. 2007;112:995-1000.
15. Basu S, Mavi A, Cermik T, Houseni M, Alavi A. Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography predict tumor biology? Mol Imaging Biol. 2008;10:62-66.
16. de Geus-Oei LF, van der Heijden HF, Corstens FH, Oyen WJ. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer. 2007;110:1654-1664.
17. 18F- fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression. J Neurooncol. 2008;87:165-171.
18. van Baardwijk A, Baumert BG, Bosmans G, et al. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev. 2006;32:245-260.
19. Grégoire V, Haustermans K, Geets X, Roels S, Lonneux M. PET-based treatment planning in radiotherapy: a new standard? J Nucl Med. 2007;48(suppl 1):68S-77S.
20. Senan S, De Ruysscher D. Critical review of PET-CT for radiotherapy planning in lung cancer. Crit Rev Oncol Hematol. 2005;56:345-351.
21. Alavi A, Dann R, Chawluk J, Alavi J, Kushner M, Reivich M. Positron emission tomography imaging of regional cerebral glucose metabolism. Semin Nucl Med. 1986;16:2-34.
22. Jamieson D, Alavi A, Jolles P, Chawluk J, Reivich M. Positron emission tomography in the investigation of central nervous system disorders. Radiol Clin North Am. 1988;26:1075-1088.
23. Jolles PR, Chapman PR, Alavi A. PET, CT, and MRI in the evaluation of neuropsychiatric disorders: current applications. J Nucl Med. 1989;30:1589-1606.
24. Wegener WA, Alavi A. Positron emission tomography in the investigation of neuropsychiatric disorders: update and comparison with magnetic resonance imaging and computerized tomography. Int J Rad Appl Instrum B. 1991;18:569-582.
25. Bacskai BJ, Klunk WE, Mathis CA, et al. Imaging amyloid-beta deposits in vivo. J Cereb Blood Flow Metab. 2002;22:1035-1041.
26. Duncan JS. Imaging and epilepsy. Brain. 1997;120(Pt 2):339-377.
27. Guadagno JV, Calautti C, Baron JC. Progress in imaging stroke: emerging clinical applications. Br Med Bull. 2003;65:145-57.
28. Heiss WD, Kracht LW, Thiel A, Grond M, Pawlik G. Penumbral probability thresholds of cortical flumazenil binding and blood flow predicting tissue outcome in patients with cerebral ischaemia. Brain. 2001;124(Pt 1):20-29.
29. 18F-fluorodeoxyglucose and positron emission tomography. Neurology. 1982;32:132321329.
30. Alavi JB, Alavi A, Chawluk J, et al. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer. 1988;62:1074-1078.
31. Brock CS, Young H, O'Reilly SM, et al. Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer. 2000;82:608-615.
32. Rozental JM, Levine RL, Mehta MP, et al. Early changes in tumor metabolism after treatment: the effects of stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 1991;20:1053-1060.
33. De Witte O, Goldberg I, Wikler D, et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg. 2001;95:746-750.
34. 11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol. 1991;32:197-202.
35. O'Doherty MJ, Barrington SF, Campbell M, et al. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med. 1997;38:1575-1583.
36. 18F-DOPA-PET imaging in assessing movement disorders. Radiol Clin North Am. 2005;43:93-106.
37. 18F-DOPA PET data. J Neurol Neurosurg Psychiatr. 1994;57:278-284.
38. Antonini A, Leenders KL, Spiegel R, et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain. 1996;119:2085-2095.
39. Weeks RA, Piccini P, Harding AE, Brooks DJ. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol. 1996;40:49-54.
40. Schwaiger M, Ziegler S, Nekolla SG. PET/CT: challenge for nuclear cardiology. J Nucl Med. 2005;46:1664-1678.
41. Lodge MA, Braess H, Mahmoud F, et al. Developments in nuclear cardiology: transition from single photon emission computed tomography to positron emission tomography-computed tomography. J Invasive Cardiol. 2005;17:491-496.
42. Takalkar A, Mavi A, Alavi A, Araujo L. PET in cardiology. Radiol Clin North Am. 2005;43:107-119, xi.
43. Schelbert HR. Blood flow and metabolism by PET. Cardiol Clin. 1994;12:303-315.
44. Di Carli MF, Dorbala S, Meserve J, El Fakhri G, Sitek A, Moore SC. Clinical myocardial perfusion PET/CT. J Nucl Med. 2007;48:783-793.
45. Couturier O, Luxen A, Chatal JF, Vuillez JP, Rigo P, Hustinx R. Fluorinated tracers for imaging cancer with positron emission tomography. Eur J Nucl Med Mol Imaging. 2004;31:1182-1206.
46. 18F-FLT PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging. 2004;31:1659-1672.
47. Lucignani G. Aptamers and in-beam PET for advanced diagnosis and therapy optimisation. Eur J Nucl Med Mol Imaging. 2006;33:1095-1097.
48. Weber WA, Wieder H. Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging. 2006;33(suppl 1):27-37.
49. Hustinx R, Eck SL, Alavi A. Potential applications of PET imaging in developing novel cancer therapies. J Nucl Med. 1999;40:995-1002.
50. Tjuvajev JG, Doubrovin M, Akhurst T, et al. Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. J Nucl Med. 2002;43:1072-1083.
51. Bennett JJ, Tjuvajev J, Johnson P, et al. Positron emission tomography imaging for herpes virus infection: implications for oncolytic viral treatments of cancer. Nat Med. 2001;7:859-863.
52. Jacobs A, Voges J, Reszka R, et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet. 2001;358:727-729.
53. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med. 1971;133:275-288.
54. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
55. Haubner R, Wester HJ, Burkhart F, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001;42:326-336.
56. 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617-1626.
57. 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging. 2006;33:460-466.
58. 68Ga. Eur J Nucl Med Mol Imaging. 2005;32:478-485.
59. Blankenberg FG, Tait JF, Strauss HW. Apoptotic cell death: its implications for imaging in the next millennium. Eur J Nuclear Med. 2000;27:359-367.
60. Blankenberg FG, Katsikis PD, Tait JF, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA. 1998;95:6349-6354.
61. Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;24:2793-2799.
62. Rajendran JG, Schwartz DL, O'Sullivan J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;12:5435-5441.
63. Fujibayashi Y, Taniuchi H, Yonekura Y, et al. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155-1160.
64. Evans SM, Hahn S, Pook DR, et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res. 2000;60:2018-2024.
65. 18F-EF5. Eur J Nucl Med Mol Imaging. 2003;30:259-266.
66. 18F-FLT PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging. 2004;31:1659-1672.
67. El-Haddad G, Zhuang H, Gupta N, Alavi A. Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med. 2004;34:313-329.
68. 18F- fluorodeoxyglucose positron emission tomography. Clin Microbiol Rev. 2008;21:209-224.
69. 18F-labeled fluorodeoxyglucose PET in the management of patients with arthroplasty. Radiol Clin North Am. 2007;45:711-78, vii.
70. Basu S, Chryssikos T, Houseni M, et al. Potential role of FDG PET in the setting of diabetic neuro-osteoarthropathy: can it differentiate uncomplicated Charcot's neuroarthropathy from osteomyelitis and soft-tissue infection? Nucl Med Commun. 2007;28:465-472.
71. 18F-FDG PET: illusion or reality? A critical review of the literature data. Eur J Nucl Med Mol Imaging. 2003;30:1305-1313.
72. Zhuang H, Yu JQ, Alavi A. Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiol Clin North Am. 2005;43:121-134.
73. Schöder H, Erdi YE, Larson SM, Yeung HW. PET/CT: a new imaging technology in nuclear medicine. Eur J Nucl Med Mol Imaging. 2003;30:1419-1437.
74. Basu S, Alavi A. Feasibility of automated partial volume correction of standardized uptake values in the current generation PET-CT scanners: Can the manufacturers provide this as integrated ready-to-use software? J Nucl Med (in press).
75. Hargreaves RJ. The role of molecular imaging in drug discovery and development. Clin Pharmacol Ther. 2008;83:349-353.
76. 18F-fluorothymidine positron emission tomography. Cancer Res. 2006;66:7621-7629.
77. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer. 2003;39:2012-2020.
78. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer. 2002;38(suppl 5):S60-S65.